These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 1061994)
1. [Biogenic amines and schizophrenia]. Schöpf J Schweiz Med Wochenschr; 1975 Sep; 105(38):1201-9. PubMed ID: 1061994 [TBL] [Abstract][Full Text] [Related]
2. Novel pharmacological approaches to the treatment of schizophrenia. Fink-Jensen A Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983 [TBL] [Abstract][Full Text] [Related]
3. Biochemistry and the schizophrenia. Old concepts and new hypothesis. Berger PA J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786 [TBL] [Abstract][Full Text] [Related]
4. [Biochemistry of schizophrenia and mechanism of action of neuroleptics]. Loo H; Cuche H; Sechter D Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604 [TBL] [Abstract][Full Text] [Related]
5. [Psychotropic drugs as tools for clinical research into schizophrenia (author's transl)]. Beckmann H Fortschr Neurol Psychiatr Grenzgeb; 1978 Oct; 46(10):564-77. PubMed ID: 29831 [TBL] [Abstract][Full Text] [Related]
6. [Psychopathology of schizophrenia and brain imaging]. Gross G; Huber G Fortschr Neurol Psychiatr; 2008 May; 76 Suppl 1():S49-56. PubMed ID: 18461545 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology and pathophysiology of dopaminergic neurons. Hornykiewicz O Adv Cytopharmacol; 1971 May; 1():369-77. PubMed ID: 4950404 [No Abstract] [Full Text] [Related]
8. Facilitation of dopamine-mediated locomotor activity in adult rats following cholinergic denervation. Mattsson A; Ogren SO; Olson L Exp Neurol; 2002 Mar; 174(1):96-108. PubMed ID: 11869038 [TBL] [Abstract][Full Text] [Related]
9. [Biological markers in schizophrenia]. Lembreghts M; Ansseau M Encephale; 1993; 19(5):501-23. PubMed ID: 8306920 [TBL] [Abstract][Full Text] [Related]
10. Dopamine receptors and the dopamine hypothesis of schizophrenia. Seeman P Synapse; 1987; 1(2):133-52. PubMed ID: 2905529 [TBL] [Abstract][Full Text] [Related]
11. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis]. Potvin S; Stip E; Roy JY Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543 [TBL] [Abstract][Full Text] [Related]
12. A critique of the dopamine hypothesis of schizophrenia and psychosis. Moncrieff J Harv Rev Psychiatry; 2009; 17(3):214-25. PubMed ID: 19499420 [TBL] [Abstract][Full Text] [Related]
13. The significance of some biochemical abnormalities in schizophrenia. Rodnight R Acta Neurol (Napoli); 1975; 30(1):85-101. PubMed ID: 1063539 [No Abstract] [Full Text] [Related]
14. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia. Haleem DJ J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192 [TBL] [Abstract][Full Text] [Related]
15. The relationship between epilepsy and schizophrenia: a biochemical hypothesis. Trimble M Biol Psychiatry; 1977 Apr; 12(2):299-304. PubMed ID: 15665 [TBL] [Abstract][Full Text] [Related]
16. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350 [TBL] [Abstract][Full Text] [Related]
17. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Ohara K Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):469-74. PubMed ID: 17184889 [TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of schizophrenia and the striatum. Klawans HL; Goetz C; Westheimer R Dis Nerv Syst; 1972 Nov; 33(11):711-9. PubMed ID: 4266033 [No Abstract] [Full Text] [Related]
19. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Oades RD; Klimke A; Henning U; Rao ML Hum Psychopharmacol; 2002 Jan; 17(1):15-27. PubMed ID: 12404703 [TBL] [Abstract][Full Text] [Related]